Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Approval Delay for Janssen’s Spravato?

Third-Party Intervention Raises EU Approval Timing Question

Executive Summary

The EMA has received written interventions from third parties relating to its CHMP opinion that the controversial antidepressant should receive EU approval.

You may also be interested in...



J&J’s Spravato Gets EU Okay For Drug-Resistant Depression

Concerns that written interventions might delay the expected EU approval of the novel ketamine-based antidepressant have come to naught.

Axsome Soars After Depression Trial Success

Axsome is set to file for approval in the second half of 2020.

Australia Consults On Improving Sponsor Access To Tailored Safety Data

The Australian regulator is looking at more efficient ways of providing drug companies with access to the product-related adverse event data they need to fulfil their pharmacovigilance responsibilities.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141361

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel